AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
Phase 2
Terminated
- Conditions
- Previously Treated Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT02087176
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Phase 2
Completed
- Conditions
- Gout and Hyperuricemia
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 204
- Registration Number
- NCT02078219
- Locations
- 🇯🇵
Research Site, Shinagawa-ku, Japan
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: BenralizumabBiological: Placebo
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 220
- Registration Number
- NCT02075255
- Locations
- 🇺🇦
Research Site, Vinnytsia, Ukraine
A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT02072993
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Post Marketing Surveillance of Roflumilast in Korea
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1837
- Registration Number
- NCT02068456
Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Phase 4
Completed
- Conditions
- Stable Coronary Heart Disease (CHD)
- Interventions
- Drug: Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT02064985
- Locations
- 🇨🇳
Research Site, Beijing, China
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT02063230
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02063204
- Locations
- 🇺🇸
Research Site, Orlando, Florida, United States
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02060201
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Asthma
- Interventions
- Drug: LAS190792 Dose 1Drug: LAS190792 Dose 2Drug: PlaceboDrug: LAS190792 Dose 2 (Part 2)Drug: LAS190792 Dose 5Drug: LAS190792 Dose 3Drug: LAS190792 Dose 4Drug: LAS190792 Dose 6Drug: LAS190792 Dose 1 (Part 2)
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT02059434
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd (MEU), Manchester, United Kingdom
🇬🇧Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom